DRL files ANDA for Rabeprazole Sodium

By SiliconIndia   |   Thursday, 20 November 2003, 08:00 Hrs
Printer Print Email Email
HYDERABAD: Dr. Reddy's Laboratories today filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA). The ANDAv was filed for Rabeprazole Sodium delayed-release tablets, 20 mg, with a Paragraph IV certification on the two Orange Book patents listed for the drug.

Dr. Reddy's notified Eisai, upon which the latter filed a lawsuit against the company in the United States District Court for the southern district of New York alleging patent infringement on the '552 patent, the release issued to the BSE said.

SPOTLIGHT
Facebook denies cyber attack
Facebook ruled out a cyber attack on its products Whatsapp, Instagram and Messenger, which suf..
Google's Gboard gets offline
Google is adding an Artificially Intelligent (AI) offline dictation feature on its Gboard keyb..
IBM announces programme
n a bid to recognise the contribution of developers in the open source community, Information ..
Wipro opens third industrial
IT major Wipro Ltd on Thursday opened its centre of excellence for Industrial Internet of Things (..